MANNKIND CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.73 USD | +1.72% |
|
0.00% | +29.95% |
| 05-29 | MannKind Agrees to Cross License Deal With Pulmatrix | MT |
| 05-29 | Pulmatrix, Inc. Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 266.3 | 728 | 1,098 | 1,387 | 981.3 | 1,288 | - | - |
| Enterprise Value (EV) 1 | 266.3 | 728 | 1,098 | 1,387 | 679 | 1,040 | 1,015 | 963.4 |
| P/E ratio | -4.78 x | -12 x | -13.7 x | -15.5 x | -91 x | 41.1 x | 21.5 x | 12.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 4.22 x | 11.2 x | 14.6 x | 13.9 x | 4.93 x | 4.73 x | 4.04 x | 3.44 x |
| EV / Revenue | 4.22 x | 11.2 x | 14.6 x | 13.9 x | 3.41 x | 3.82 x | 3.19 x | 2.57 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | -81.3 x | 5.53 x | 8.06 x | 5.77 x |
| FCF Yield | - | - | - | - | -1.23% | 18.1% | 12.4% | 17.3% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 206,408 | 232,601 | 251,256 | 263,196 | 269,575 | 272,316 | - | - |
| Reference price 2 | 1.290 | 3.130 | 4.370 | 5.270 | 3.640 | 4.730 | 4.730 | 4.730 |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 63.04 | 65.14 | 75.44 | 99.77 | 199 | 272.3 | 318.5 | 374.9 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -44.6 | -34.68 | -47.02 | -64.11 | 8.678 | 66.91 | 91.79 | 143.3 |
| Operating Margin | -70.75% | -53.24% | -62.33% | -64.26% | 4.36% | 24.57% | 28.82% | 38.23% |
| Earnings before Tax (EBT) 1 | -51.9 | -57.46 | -80.93 | -87.4 | -10.38 | 37.43 | 72.94 | 129 |
| Net income 1 | -51.9 | -57.24 | -80.93 | -87.4 | -11.94 | 35.41 | 70.37 | 119.1 |
| Net margin | -82.34% | -87.87% | -107.27% | -87.6% | -6% | 13% | 22.09% | 31.76% |
| EPS 2 | -0.2700 | -0.2600 | -0.3200 | -0.3400 | -0.0400 | 0.1150 | 0.2200 | 0.3660 |
| Free Cash Flow 1 | - | - | - | - | -8.347 | 188 | 126 | 167 |
| FCF margin | - | - | - | - | -4.2% | 69.04% | 39.56% | 44.55% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | 530.95% | 179.06% | 140.27% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 12.52 | 11.99 | 18.89 | 32.82 | 36.06 | 40.63 | 48.61 | 51.25 | 58.47 | 66.26 | 65.59 | 67.85 | 72.58 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -23.97 | -21.26 | -20.45 | -9.61 | -12.79 | -5.998 | 1.721 | 5.097 | 7.858 | 16.72 | 14.75 | 15.56 | 16.38 |
| Operating Margin | -191.51% | -177.25% | -108.26% | -29.28% | -35.47% | -14.76% | 3.54% | 9.94% | 13.44% | 25.24% | 22.49% | 22.93% | 22.57% |
| Earnings before Tax (EBT) 1 | -28.06 | -26 | -29.02 | -14.43 | -17.95 | -9.795 | -5.265 | 1.721 | 2.962 | 10.89 | 2.691 | 11.1 | 12.71 |
| Net income 1 | -28.06 | -26 | -29.02 | -14.43 | -17.95 | -9.795 | -5.265 | 1.721 | 1.401 | 10.63 | 1.818 | 10.68 | 12.13 |
| Net margin | -224.22% | -216.79% | -153.61% | -43.97% | -49.77% | -24.11% | -10.83% | 3.36% | 2.4% | 16.04% | 2.77% | 15.73% | 16.71% |
| EPS 2 | -0.1100 | -0.1000 | -0.1100 | -0.0600 | -0.0700 | -0.0400 | -0.0200 | 0.0100 | 0.004300 | 0.0400 | 0.0100 | 0.0320 | 0.0340 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 5/5/22 | 8/9/22 | 11/8/22 | 2/23/23 | 5/9/23 | 8/7/23 | 11/7/23 | 2/27/24 | 5/8/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | 302 | 248 | 273 | 325 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | -8.35 | 188 | 126 | 167 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 2.57 | 0.8 | 11.5 | 7.59 | 42.4 | 11 | 14 | 18 |
| Capex / Sales | 4.07% | 1.23% | 15.2% | 7.61% | 21.33% | 4.04% | 4.4% | 4.8% |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.73
USD
Average target price
7.083
USD
Spread / Average Target
+49.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.95% | 1.27B | |
| +16.93% | 124B | |
| +17.01% | 109B | |
| -7.23% | 23.84B | |
| +1.98% | 22.42B | |
| -14.29% | 17.5B | |
| -6.79% | 16.61B | |
| -37.63% | 16.43B | |
| +2.17% | 13.4B | |
| +24.42% | 11.47B |
- Stock Market
- Equities
- MNKD Stock
- Financials MannKind Corporation
